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SResults: Eighty four patients were included in the ﬁnal analysis. Device position post-
deployment was signiﬁcantly higher than pre-deployment (16.112.5% vs.
33.712.5%, p<0.0001). Operator-independent cranial movement during deployment
was 2.41.6 mm (range -0.35 to 6.8 mm). There was foreshortening of the device
during deployment with lower edge of the valve moving farther cranially than the
upper edge (3.61.7 vs. 1.31.6 mm, p <0.0001). This movement was similar
between valve versions and vascular access. There was a trend (p ¼ 0.09) for more
movement with the 29 mm valve. Valve movement was not signiﬁcantly related to
echo parameters listed in Table 1.
Conclusions: Operator-independent cranial movement of the balloon-expandable
transcatheter valve occurs during its deployment. There is device foreshortening with
deployment explained by the fact that caudal edge of the device moves farther than the
cranial edge. This deployment movement of the device can be characterized by TEE
and may help with positioning immediately prior to valve deployment.Table 1. Transcatheter aortic valve movement during valve deployment
Device Movement
(midline), (mm) p
Valve Type
SAPIEN (n ¼ 53) 2.391.64 0.686
SAPIEN XT (n ¼ 31) 2.541.65
Valve Size (mm)
23 (n ¼ 25) 2.171.83 0.53 (23 vs.26)
0.077 (23 vs.29)
0.095 (26 vs.29)
26 (n ¼ 51) 2.431.58
29 (n ¼ 8) 3.411.02
Access
Transfemoral (TF), (n ¼
72)
2.451.65 0.87 (TF vs. TA)
0.84 (TF vs. Tao)
0.80 (TA vs. Tao)Transapical (TA), (n ¼ 8) 2.341.65
Transaortic (Tao), (n ¼
4)
2.611.72
AV Area (cm2)
<0.67 (n ¼ 41) 2.471.79 0.89
0.67 (n ¼ 43) 2.421.50
Aortic Annulus Diameter (mm)
<23 (n ¼ 38) 2.371.77 0.72
23 (n ¼ 46) 2.501.53
Interventricular septal thickness (mm)
>1.3 (n ¼ 53) 2.38 1.57 0.65
1.3 (n ¼ 31) 2.55 1.76
Valve Calciﬁcation by TEE
no/mild (n ¼ 39) 2.411.54 0.85
moderate/severe (n ¼
45)
2.471.73
Sinus Volume (cm3) by TEE
<7.6 (n ¼ 42) 2.371.70 0.68
7.6 (n ¼ 42) 2.521.58
*consecutive patients who had cardiac CT angiography as part of preoperative evaluation.TCT-745
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Background: Accurate measurement of the aortic annulus and adherence to over-
sizing principles are crucial for transcatheter aortic valve replacement (TAVR). We
sought to assess adherence to transcatheter heart valve (THV) oversizing principles
according to transesophageal echocardiography (TEE) and computed tomography
(CT) and to evaluate the relationship between the adherence to oversizing and clinical
outcome.
Methods: Between 2009 and 2010, 157 aortic stenosis patients underwent screening CT
prior to CoreValve implantation. During this early experience, CT was performed only to
evaluate the peripheral vasculature. In all cases, TAVR-sizing was performed using TEE.
CT datasets were retrospectively reconstructed and the CTmean, CTarea, andCTperimeterJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrdimensions were measured. TEE and CT diameters were used to determine oversizing.
Signiﬁcant paravalvular leak (PVL) (grade 2)was the primary clinical outcomemeasure.
Results: TEE-derived diameters were signiﬁcantly smaller than CT-based measure-
ments (p<0.0001). According to TEE and CTperimeter, 95.5% and 78.3% were
suitable for CoreValve implantation (26/29mm), respectively. Using TEE, 80.9%
received the appropriate valve size, while CTperimeter suggested that only 51.0% met
oversizing criteria. The average oversizing with TEE 20.28.3% compared to
10.18.6% with CTperimeter. After CoreValve implantation, 38 (24.2%) patients had
signiﬁcant PVL. PVL was similar among patients that satisﬁed and those that did not
satisfy sizing criteria using TEE (23.6%vs26.7%,p¼0.813). When CT data was
applied, PVL was signiﬁcantly lower in those that satisﬁed sizing criteria
(CTperimeter: 13.8%vs35.1%,p¼0.0026). Adherence to CT but not TEE-sizing, was
associated with a reduction in PVL (CTperimeter:odds ratio:0.30;95% CI:0.
13-0.65,p¼0.002). Sensitivity-speciﬁcity curves for CTperimeter identiﬁed minimal
oversizing thresholds of 9.0% and 9.6% for the 26 and 29mm CoreValves that best
predicted PVL.
Conclusions: Compared to TEE, CT-based THV-sizing yields larger annular diam-
eters, changes the selected valve size in half of all patients, and is predictive of PVL.
CTperimeter is the most sensitive CT measurement for predicting PVL.
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Background: Objectives: To compare the cerebral embolic load, assessed by diffu-
sion weighted magnetic resonance imaging (DW-MRI), after percutaneous implan-
tation of Edwards Sapien XT (SXT) versus Direct Flow Medical aortic valve (DFM)
implantation. Background: New cerebral ischemic lesions after percutaneous
implantation of commercially available aortic valves are found in more than 80% of
patients. The DFM is a non-metallic prosthesis, which is placed pulling it through the
left ventricular outﬂow tract up to the aortic annulus, jailing the native valve behind
a polymer cuff. It is unknown whether this impacts the risk of cerebral embolization.
Methods: We performed a DW-MRI the day before and 48 to 72 h after TAVI. DW-
MRI studies were blindly analyzed by a radiologist, and all patients had a neurological
assessment before and after the procedure.
Results: In 36 consecutive patients (mean age 82.8  4.9 years, 56 % male) with
severe symptomatic aortic stenosis and high surgical risk were studied. In a SXT (16
pts), a DFM (20 pts) was successfully implanted via the femoral artery. There was no
difference in patient demographics as well as in the log EuroScore and in comor-
bidities between both groups. All pts underwent a balloon valvuloplasty before and 1
pt with SXT also after valve implantation. None of the pts had a stroke or TIA. The
incidence of new cerebral ischemic lesions did not differ signiﬁcantly in with DFM
compared to SXT pts. (17/20, 85%, versus 10/16, 62.5%, p¼0.12). However, new
ischemic lesions were more frequently found in both hemispheres in DFM compared
to SXT patients (55% vs. 18.8%, p¼0.03). The number of ischemic lesions per patient
was signiﬁcantly higher in DFM patients (3.3 2.6 for DFM vs 1.7  2.5 for SXT,
p¼0.049). For the volume of lesions there was a trend in favour of SXT (0.17 ml 0.3
cm3 vs.0.34 ml  0.56cm3, p¼0.2).
Conclusions: The type of valve prosthesis for percutaneous treatment of severe aortic
stenosis may have an impact on cerebral embolization.
TCT-747
Transcatheter Aortic Valve Replacement: Assessment of the Learning Curve
Based on the PARTNER Trial
Oluseun Alli1, Charanjit Rihal2, Rakesh Suri2, Kevin Greason2, Ron Waksman3,
Sa'ar Minha4, Rebecca Torguson5, Augusto Pichard6, Michael Mack7,
Lars Svensson8, Jeevanantham Rajeswaran9, Ashley M. Lowry9, Eugene Blackstone9,
E. Murat Tuzcu10, Vinod Thourani11, Raj Makkar12, Martin Leon13,
David Holmes Jr14
1University of Alabama at Birmingham, Birmingham, AL, 2Mayo Clinic, Rochester,
MN, 3MedStar Health Research Institute, Washington, DC, 4MedStar Washington
Hospital Center, Washington, DC, 5Washington Hospital center, washington, DC,
6washsington hospital center, Washington, United States, 7Baylor Healthcare System,
Plano, United States, 8Cleveland Clinic, Cleveland, USA, 9Cleveland Clinic,
Cleveland, OH, 10Cleveland Clinic Foundation, Cleveland, Ohio, 11Emory University,
Atlanta, GA, 12Associate Prof, UCLA school of Medicine, Los Angeles, California,
13Cardiovascular Research Foundation, New York, NY, 14Mayo Clinic College of
Medicine, Rochester, United States
Background: Transcatheter aortic-valve replacement (TAVR) is a new procedure for
the treatment of severe aortic stenosis. The number of cases require to gain proﬁciency
"learning curve" is unknown. The aim of this study is to assess the learning curve of
the team involved in the performance of TAVR in the PARTNER trial. We hypoth-
esized that a) a quantiﬁable learning curve exists for TAVR and b) process measures
of procedural proﬁciency would improve with increasing case volumesacts/POSTER/Aortic Valve Disease and Treatment B227
